|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
News and Press
  |
|
|
|
 |
|
 |
COSTA MESA, California – October 20, 2002 – At the American Academy of Ophthalmology meeting in Orlando, OKTO Ophtho, the premier developer and distributor of specialty technologies for eye surgery, launched the AmbioDry™ Dehydrated Amniotic Membrane Allografts for eye surgery. Initially detailed clinically by physicians in the 1940’s, the use of human amniotic membrane transplantation by ophthalmologist to surgically treat ocular surface disorders has been revived during the past 15 years. Dr. Batlle, a world-renown ophthalmologist, is the recognized innovator and pioneer of preserved amniotic membrane for ophthalmic surgery. In 1993, at the American Academy Meeting in Chicago, and at subsequent meeting throughout the past 10 years, Dr. Batlle presented his experiences employing preserved human amniotic membrane for the surgical treatment of pterygium, dermoids, fornix reconstruction, alkali burns and bullous keratopathy. Dr. Batlle is a member of the OKTO Surgical Advisory Board. “Today marks a revolutionary step forward towards significantly improving surgical performance and outcomes in ocular surface surgery, “ said Erich Ziegler, President/CEO of OKTO. “The technology and utility advantages of the AmbioDry technology, compared to current, alternative options, are significant and vast. We’ve worked extremely hard on this developing the technology. Our whole team should be proud.” The advantages of the AmbioDry are vast: decellularized, sterile tissue matrix; shelf-life storage; prepares in minutes for surgery; substrate-free; consistent tissue quality. About OKTO Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider. OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive surgeries. Media Contact:
|
|